MedTrace Logo

Investigating Loss of Neuromuscular Junction Transmission Fidelity in Older Adults

NCT04904926 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2021-11-11

No results posted yet for this study

Summary

Sarcopenia is a condition characterised by age-related loss of muscle mass and function. Factors affecting the strength of muscle contraction independent of mass, such as neuromuscular junction (NMJ) transmission, are increasingly suspected as important contributors to the development of age-related physical disability. The group of investigators leading the current study, have recently demonstrated NMJ transmission deficits in aged mice, but whether this translates in older human individuals is not known

The primary aim is to assess whether clinically meaningfull muscle weakness is associated with NMJ transmission deficits in older human individuals with clinically meaningfull muscle weakness.

The secondary aim is to assess whether NMJ transmission deficits correlate with different measures of functional capacity to inform future trials of the most appropriate choice of tests.

Conditions

Sponsors & Collaborators

  • Ohio University

    collaborator OTHER

  • Ohio State University

    collaborator OTHER

  • NMD Pharma A/S

    lead INDUSTRY

Principal Investigators

  • Brian Clark, PhD · Ohio University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-16
Primary Completion
2021-09-22
Completion
2021-09-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04904926 on ClinicalTrials.gov